悦康药业亮相BIO 2025，核酸多肽创新药管线点燃全球关注热潮

Group 1 - The 2025 BIO International Convention was held in Boston, attracting over 20,000 participants and more than 1,500 exhibitors, focusing on 18 key topics including AI and cell and gene therapies [1] - Yuyuan Pharmaceutical showcased its innovative pipeline in small nucleic acids and peptide drugs, highlighting its potential first-in-class and best-in-class projects [1] - The company presented its eleven leading technology platforms, emphasizing their core advantages and innovative layout in the nucleic acid and peptide fields [1] Group 2 - During the conference, Yuyuan Pharmaceutical engaged in in-depth discussions with major multinational corporations, Big Pharma, and renowned investment banks [2] - Several innovative drug projects, including YKYY015 (PCSK9 siRNA for high cholesterol), YKYY013 (HBV siRNA for hepatitis B), and YKYY025 (RSV mRNA vaccine), sparked significant interest due to their differentiated advantages [2] - The participation in the convention enhanced Yuyuan Pharmaceutical's international visibility and established a foundation for accelerating the international development and collaboration of its research pipeline [2]